Latest Developments in Follicular Lymphoma Treatment Pipeline 2023: FDA, EMA, and PMDA Approvals by AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharma

November 29 08:24 2023
Latest Developments in Follicular Lymphoma Treatment Pipeline 2023: FDA, EMA, and PMDA Approvals by AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharma
Follicular Lymphoma Pipeline

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Follicular Lymphoma pipeline constitutes 50+ key companies continuously working towards developing 50+ Follicular Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Follicular Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Follicular Lymphoma Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Follicular Lymphoma Market.


Some of the key takeaways from the Follicular Lymphoma Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Follicular Lymphoma treatment therapies with a considerable amount of success over the years. 
  • Follicular Lymphoma companies working in the treatment market are InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharmaceuticals, ADC Therapeutics, AstraZeneca, Dr Reddy’s Laboratories, MAB WORKS, and others, are developing therapies for the Follicular Lymphoma treatment 
  • Emerging Follicular Lymphoma therapies in the different phases of clinical trials are- ICP 248, ALLO-501, HMPL-689, PSB 202, Abexinostat, Loncastuximab tesirine, Acalabrutinib, DRL_RI, MIL62, and others are expected to have a significant impact on the Follicular Lymphoma market in the coming years.   
  • In June 2021, A multi-center, open-label Phase III study was started by Beijing Mabworks Biotech Co., Ltd. to compare the safety and effectiveness of MIL62 with lenalidomide to lenalidomide in patients with follicular lymphoma that was resistant to rituximab.


Follicular Lymphoma Overview

Follicular lymphoma (FL) is a B-cell lymphoma that usually grows slowly or is indolent. It is a type of non-Hodgkin lymphoma (NHL) that originates from lymphocytes. Of all NHL cases, 20 to 30 percent are of this lymphoma subtype.


Get a Free Sample PDF Report to know more about Follicular Lymphoma Pipeline Therapeutic Assessment-


Emerging Follicular Lymphoma Drugs Under Different Phases of Clinical Development Include:

  • ICP 248: InnoCare Pharma
  • ALLO-501: Allogene Therapeutics
  • PSB 202: Sound Biologics
  • Abexinostat: Xynomic Pharmaceuticals
  • Loncastuximab tesirine: ADC Therapeutics
  • Acalabrutinib: AstraZeneca
  • DRL_RI: Dr Reddy’s Laboratories


Follicular Lymphoma Route of Administration

Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal


Follicular Lymphoma Molecule Type

Follicular Lymphoma Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule


Follicular Lymphoma Pipeline Therapeutics Assessment

  • Follicular Lymphoma Assessment by Product Type
  • Follicular Lymphoma By Stage and Product Type
  • Follicular Lymphoma Assessment by Route of Administration
  • Follicular Lymphoma By Stage and Route of Administration
  • Follicular Lymphoma Assessment by Molecule Type
  • Follicular Lymphoma by Stage and Molecule Type


DelveInsight’s Follicular Lymphoma Report covers around 50+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Further Follicular Lymphoma product details are provided in the report. Download the Follicular Lymphoma pipeline report to learn more about the emerging Follicular Lymphoma therapies


Some of the key companies in the Follicular Lymphoma Therapeutics Market include:

Key companies developing therapies for Follicular Lymphoma are – Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, ADC Therapeutics, Incyte Corporation, MorphoSys, AbbVie, Janssen Research & Development, Regeneron Pharmaceuticals, Novartis, MEI Pharma, BeiGene, Xynomic Pharmaceuticals, Bristol Myers Squibb, and others.


Follicular Lymphoma Pipeline Analysis:

The Follicular Lymphoma pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Follicular Lymphoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Follicular Lymphoma Treatment.
  • Follicular Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Follicular Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Follicular Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Follicular Lymphoma drugs and therapies


Follicular Lymphoma Pipeline Market Drivers

  • Increase in prevalence of Follicular Lymphoma, emergence of effective novel therapies, increased Research and Developmental Activities are some of the important factors that are fueling the Follicular Lymphoma Market.


Follicular Lymphoma Pipeline Market Barriers

  • However, lack Of Cost-Effective Treatment, progression of disease within 2 years (POD24) in the Disease and other factors are creating obstacles in the Follicular Lymphoma Market growth.


Scope of Follicular Lymphoma Pipeline Drug Insight    

  • Coverage: Global
  • Key Follicular Lymphoma Companies: InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharmaceuticals, ADC Therapeutics, AstraZeneca, Dr Reddy’s Laboratories, MAB WORKS, and others
  • Key Follicular Lymphoma Therapies: ICP 248, ALLO-501, HMPL-689, PSB 202, Abexinostat, Loncastuximab tesirine, Acalabrutinib, DRL_RI, MIL62, and others
  • Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies
  • Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers 


Request for Sample PDF Report for Follicular Lymphoma Pipeline Assessment and clinical trials


Table of Contents

1. Follicular Lymphoma Report Introduction

2. Follicular Lymphoma Executive Summary

3. Follicular Lymphoma Overview

4. Follicular Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. Follicular Lymphoma Pipeline Therapeutics

6. Follicular Lymphoma Late Stage Products (Phase II/III)

7. Follicular Lymphoma Mid Stage Products (Phase II)

8. Follicular Lymphoma Early Stage Products (Phase I)

9. Follicular Lymphoma Preclinical Stage Products

10. Follicular Lymphoma Therapeutics Assessment

11. Follicular Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Follicular Lymphoma Key Companies

14. Follicular Lymphoma Key Products

15. Follicular Lymphoma Unmet Needs

16 . Follicular Lymphoma Market Drivers and Barriers

17. Follicular Lymphoma Future Perspectives and Conclusion

18. Follicular Lymphoma Analyst Views

19. Appendix

20. About DelveInsight


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States